Cited by 53Cancer survivorship and careLung Cancer Diagnosis and TreatmentAnxiety, Depression, Psychometrics, Treatment, Cognitive Processes

Clinical biopsychosocial risk factors for depression in lung cancer patients: a comprehensive analysis using data from the Lung Cancer Database Project

Open access
Shimizu, K., Nakaya, N., Saito-Nakaya, K., Akechi, T., Yamada, Y., Fujimori, M., Ogawa, A., Fujisawa, D. +4 more·2012·Annals of Oncology

Abstract

Background Various risk factors for depression in lung cancer patients have been suggested but have been examined separately in studies with relatively small sample sizes. The present study examined the biopsychosocial risk factors of depression in lung cancer patients, focusing on psychological factors in the largest patient sample reported to date.Patients and methods A total of 1334 consecutively recruited lung cancer patients were selected, and data on cancer-related variables, personal characteristics, health behaviors, physical symptoms, and psychological factors were obtained. The participants were divided into groups with or without depression using the Hospital Anxiety and Depression Scale.Results Among the recruited patients, 165 (12.4%) manifested depression. The results of a binary logistic regression analysis were significant (overall R2, 36.5%), and a greater risk for depression was strongly associated with psychological factors, such as personality characteristics (neuroticism) and coping style (low fighting spirit, helplessness/hopelessness, and anxious preoccupation). Although the contributions of cancer-related variables, personal characteristics, health behaviors, and clinical state were relatively low, cancer stage, cancer type, sex, and age correlated significantly with depression.Conclusion Depression was most strongly linked with personality traits and coping style, and using screening instruments to identify these factors may be useful for preventive interventions.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/annonc/mds061

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 13

  1. Sekine I, Yamamoto N, Kunitoh H et al. Relationship between objective responses in phase I trials and potential efficacy of non-specific cytotoxic investigational new drugs. Ann Oncol 2002; 13: 1300-1306.
  2. Han C, Braybrooke JP, Deplanque G et al. Comparison of prognostic factors in patients in phase I trials of cytotoxic drugs vs new noncytotoxic agents. Br J Cancer 2003; 89: 1166-1171.
  3. Bachelot T, Ray-Coquard I, Catimel G et al. Multivariate analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials. Ann Oncol 2000; 11: 151-156.
  4. Roberts TG, Jr, Goulart BH, Squitieri L et al. Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. JAMA 2004; 292: 2130-2140.
  5. Horstmann E, McCabe MS, Grochow L et al. Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med 2005; 352: 895-904.
  6. Arkenau HT, Olmos D, Ang JE et al. Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience. Br J Cancer 2008; 98: 1029-1033.
  7. Janisch L, Mick R, Schilsky RL et al. Prognostic factors for survival in patients treated in phase I clinical trials. Cancer 1994; 74: 1965-1973.
  8. Postel-Vinay S, Gomez-Roca C, Molife LR et al. Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities?. J Clin Oncol 2011; 29: 1728-1736. references
  9. Akechi T, Okamura H, Nishiwaki Y, Uchitomi Y. Psychiatric disorders and associated and predictive factors in patients with unresectable nonsmall cell lung carcinoma: a longitudinal study. Cancer 2001; 92: 2609-2622.
  10. Uchitomi Y, Mikami I, Kugaya A et al. Depression after successful treatment for nonsmall cell lung carcinoma. Cancer 2000; 89: 1172-1179.
  11. Cassileth BR, Lusk EJ, Strouse TB et al. A psychological analysis of cancer patients and their next-of-kin. Cancer 1985; 55: 72-76.
  12. Uchitomi Y, Mikami I, Kugaya A et al. Physician support and patient psychologic responses after surgery for nonsmall cell lung carcinoma: a prospective observational study. Cancer 2001; 92: 1926-1935.
  13. Akechi T, Fukue-Saeki M, Kugaya A et al. Psychometric properties of the Japanese version of the Mental Adjustment to Cancer (MAC) scale. Psychooncology 2000; 9: 395-401.

Authors
Shimizu, K., Nakaya, N., Saito-Nakaya, K., Akechi, T., Yamada, Y., Fujimori, M., Ogawa, A., Fujisawa, D., Goto, K., Iwasaki, M., Tsugane, S., & Uchitomi, Y.
Affiliations
  • National Cancer Center Hospital (JP)
  • Tohoku University (JP)
  • Nagoya City University (JP)
  • National Cancer Center Hospital East (JP)
  • National Cancer Center Research Institute (JP)
  • Okayama University (JP)
Corresponding author
Shimizu, K.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2012-08
Volume
23
Issue
8
Pages
1973-1979
ISSN
0923-7534 (ISSN-L)
OpenAlex
W2104490972
Cited by
53
References
55
Citations by year
2026: 1 · 2025: 1 · 2024: 1 · 2023: 4 · 2022: 4 · 2021: 2 · 2020: 7 · 2019: 2 · 2018: 1 · 2017: 6 · 2016: 5 · 2015: 9 · 2014: 6 · 2013: 3 · 2012: 1
FWCI
3.00
Type
journal article
Language
en
Open access
Locations
  • Annals of Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • HighWire Press Open Archive (submittedVersion)
Funders
  • Clinical Cancer Research (H22-033, H22-036)
  • Japanese Ministry of Health, Labor and Welfare
Topics
  • Health Sciences › Medicine › Oncology › Cancer survivorship and care
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
Keywords
depression, lung cancer, biopsychosocial risk factors, psychological factors, neuroticism, coping styles, helplessness, anxious preoccupation, fighting spirit, personality traits, tumor stage, depression screening
MeSH terms
Adaptation, Psychological, Adult, Aged, Aged, 80 and over, Depression, Female, Humans, Japan, Lung Neoplasms, Male, Middle Aged, Quality of Life, Risk Factors, Social Class, Logistic Models

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review